Sisunatovir Hydrochloride

N/A

Report date: 2025/03/11 11:44:15
NME

Base Information

Drug NameSisunatovir Hydrochloride
Drug Alias NameRV-521PF-07923568RV521.HCl
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionViral fusion proteins inhibitorsVirus replication inhibitors
TargetsViral fusion proteins
Therapy Area/IndicationsLower Respiratory Tract InfectionsRenal InsufficiencyHepatic Insufficiency +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[28] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesReviral Ltd
China Registration ClassN/A

Develop Information

Active CompaniesPfizer IncPatheon Uk LtdShanghai LianBio Development Co Ltd
Inactive CompaniesPfizer LtdPfizer Investment Co Ltd
Active IndicationsRenal InsufficiencyHepatic InsufficiencyLiver Diseases +[4] 
Inactive IndicationsLower Respiratory Tract InfectionsHematopoietic stem cell transplantation (HSCT)

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG